Reply to |[lsquo]|Absence of JAK-2 (Val617Phe) point mutations in multiple myeloma|[rsquo]| by Dr Qin Huang et al. referred to |[lsquo]|Screening of JAK2 V617F mutation in multiple myeloma|[rsquo]| from Fiorini A et al. published in Leukemia 2006, October 20

A Fiorini; G Farina; G Reddiconto; M Palladino; E Rossi; T Za; L Laurenti; S Giammarco; P Chiusolo; G Leone; S Sica

【24h】

Reply to |[lsquo]|Absence of JAK-2 (Val617Phe) point mutations in multiple myeloma|[rsquo]| by Dr Qin Huang et al. referred to |[lsquo]|Screening of JAK2 V617F mutation in multiple myeloma|[rsquo]| from Fiorini A et al. published in Leukemia 2006, October 20

机译：回复| [lsquo] |多发性骨髓瘤中缺少JAK-2（Val617Phe）点突变| [rsquo] |黄钦博士等。 |||||多发性骨髓瘤中JAK2 V617F突变的筛选|||来自Fiorini A等。发表于2006年10月20日的白血病

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia》 |2007年第4期|共2页
作者
A Fiorini; G Farina; G Reddiconto; M Palladino; E Rossi; T Za; L Laurenti; S Giammarco; P Chiusolo; G Leone; S Sica;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Reply to |[lsquo]|Rituximab in CD20 positive multiple myeloma|[rsquo]| by P Moreau et al. [J] . P T Greipp, P Kapoor, W G Morice, Leukemia . 2008,第1期

机译：回复| [lsquo] |利妥昔单抗在CD20阳性多发性骨髓瘤| [rsquo] |由P Moreau等人。
2. Reply to |[lsquo]|Rituximab activity in CD20-positive multiple myeloma|[rsquo]| [J] . A Gozzetti, A Fabbri, S Lazzi, Leukemia . 2008,第5期

机译：回复| [lsquo] | CD20阳性多发性骨髓瘤中的利妥昔单抗活性| [rsquo] |
3. Reply to |[lsquo]|Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML|[rsquo]| by Summers et al. [J] . C G Nyvold, H B Ommen, M ?stergaard, Leukemia . 2007,第3期

机译：回复| [| ls || Wilms的肿瘤1突变与FLT3-ITD和正常核型AML患者中标准诱导化疗的失败有关|||萨默斯等人。
4. Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation [O] . Satoko Oka, Kazuo Ono, Masaharu Nohgawa -1

机译：阿扎胞苷成功治疗多发性骨髓瘤和急性髓细胞白血病同时发生并伴有del（5q）和JAK2 V617F突变
5. Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation [O] . Satoko Oka, Kazuo Ono, Masaharu Nohgawa 2017

机译：用Concompant Del（5Q）和JAK2 V617F突变同时发生氮己酸酯的同时发生多发性骨髓瘤和急性髓性白血病

Reply to |[lsquo]|Absence of JAK-2 (Val617Phe) point mutations in multiple myeloma|[rsquo]| by Dr Qin Huang et al. referred to |[lsquo]|Screening of JAK2 V617F mutation in multiple myeloma|[rsquo]| from Fiorini A et al. published in Leukemia 2006, October 20

著录项

相似文献

相关主题

期刊订阅